SCHEMBL2120774

SCHEMBL2120774

O=C(O)N1C=Cc2ccccc2C=C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 8/20 0.39
TSHR P16473 2/20 0.38
ATM Q13315 1/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
SCN4A P35499 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
ALDH1A1 P00352 2/20 0.35
CES2 O00748 2/20 0.35
CES1 P23141 2/20 0.35
DAO P14920 1/20 0.35
NAPRT Q6XQN6 1/20 0.35
ALOX15 P16050 1/20 0.35
P2RX1 P51575 2/20 0.33
P2RX3 P56373 2/20 0.33
P2RX7 Q99572 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753850 0.79 TSHR (0.50) P2RX4TSHRATMLMNAMAPK1
SCHEMBL4006006 0.78 KDM4E (0.36) TSHRLMNAALDH1A1CES2CES1
SCHEMBL4664953 0.74 NOTUM (0.39) P2RX4TSHRLMNAMAPK1SCN4A
SCHEMBL4538395 0.74 MAPK1 (0.37) P2RX4TSHRATMLMNAMAPK1
SCHEMBL31481251 0.74 MEN1 (0.36) MEN1KMT2A
Bicarbonate SCHEMBL9350415 0.73 P2RX4 (0.48) P2RX4TSHRLMNAMAPK1SCN4A
SCHEMBL29467532 0.71 P2RX4 (0.45) P2RX4TSHRATMLMNAMAPK1
SCHEMBL304994 0.67 HDAC3 (0.43) P2RX4TSHRATMALDH1A1ALOX15
SCHEMBL7347447 0.67 CA12 (0.36) P2RX4TSHRATMLMNAMAPK1
SCHEMBL7182054 0.67 P2RX4 (0.33) P2RX4TSHRATMLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
US-20140332772-A1 STYRL-BASED COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2014-11-13 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed
EP-2443110-A1 S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING Glaxo Group Limited (GB) 2012-04-25 EP disclosed
US-20070208005-A1 TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-09-06 US disclosed
EP-1406902-B1 HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN CO LLC (US) 2005-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 P2RX4 179/4885TSHR 262/4885ATM 4473/4885
US-20070208005-A1 TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 P2RX4 363/4885TSHR 395/4885ATM 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.